AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials
A DeepMind spinoff has developed AI-designed drugs that are now set to enter human trials. These drugs represent a novel approach to utilizing artificial intelligence in drug development.
More in Research
What Anthropic’s latest AI discovery does—and doesn’t—show
Anthropic just revealed new insights about AI alignment and safety. Their findings could lead to better understanding and control of AI behaviors in future models.
Scientists’ Side Hustle? Using AI and Quantum Computing to Generate New Peptides
Scientists are using AI and quantum computing to generate new peptides. This approach could accelerate drug discovery and lead to more effective treatments.
The Download: Claude’s inner workings and OpenAI’s “super app”
Anthropic is revealing the inner workings of Claude, detailing its architecture and capabilities. This transparency aims to enhance user trust and understanding of how Claude operates in various applications.
Can AI answer the $3 trillion question?
TechCrunch explores how AI could tackle the $3 trillion question of global economic challenges. By leveraging advanced models, AI aims to provide insights that could reshape economic strategies and decision-making.